FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891917869> ?p ?o ?g. }

• W2891917869 endingPage "218" @default.
• W2891917869 startingPage "211" @default.
• W2891917869 abstract "Patient-reported outcomes (PROs) can assist clinicians in understanding the impact of disease-modifying therapy (DMT) on the daily lives of patients with multiple sclerosis (MS). With an increased number of DMTs becoming available, patients are now switching treatments more frequently in clinical practice. The effects of switching DMTs on a patient's daily life and their disease course may be reflected in PROs. The global, multicenter, open-label, phase 4 Teri-PRO study (NCT01895335), which was conducted in routine clinical practice, previously showed statistically and clinically significant increases in patient-reported treatment satisfaction in patients switching to teriflunomide from other DMTs. The impact of switching to teriflunomide from other DMTs on treatment satisfaction and a range of additional PROs was also evaluated.Patients with relapsing forms of MS (N = 1000) received teriflunomide for 48 weeks per local labeling. Outcomes assessed in this analysis included treatment satisfaction (as measured by Treatment Satisfaction Questionnaire for Medication [Version 1.4]), disability worsening (as measured using the Expanded Disability Status Scale [EDSS] score, the Patient-Determined Disease Steps scale, and the Multiple Sclerosis Performance Scale), cognition (as measured using the Symbol Digit Modalities Test [SDMT]), treated relapses, quality of life (as measured by the Multiple Sclerosis International Quality of Life [MusiQoL] questionnaire and the Stern Leisure Activity Scale), and safety/tolerability over the course of the study in the subgroup of patients switching to teriflunomide from another DMT (n = 594).Patients reported significant improvements in treatment satisfaction scores following the switch to teriflunomide regardless of the reason for treating with teriflunomide (Global Satisfaction, disease worsening: baseline, 46.0, Week 48, 65.1; convenience: baseline, 57.4, Week 48, 72.4; intolerance: baseline, 50.9, Week 48, 71.1; side effects: baseline, 49.7, Week 48, 67.2; P < 0.0001 in all comparisons). These patients also showed improvement or stability in PROs evaluating disability worsening, cognition, and quality of life (EDSS: baseline, 3.1, Week 48, 3.0; SDMT: baseline, 0.975, Week 48, 0.978; MusiQoL: baseline, 67.5, Week 48, 69.5). The safety and tolerability profile of teriflunomide was consistent with that observed in other teriflunomide clinical trials.This analysis of the Teri-PRO study demonstrates the value of switching to teriflunomide from other DMTs in a real-world, clinical practice setting. The high levels of treatment satisfaction associated with teriflunomide in Teri-PRO may lead to improved adherence and thus improved outcomes." @default.
• W2891917869 created "2018-09-27" @default.
• W2891917869 creator A5012376027 @default.
• W2891917869 creator A5017709518 @default.
• W2891917869 creator A5022338962 @default.
• W2891917869 creator A5026008723 @default.
• W2891917869 creator A5026649268 @default.
• W2891917869 creator A5036189855 @default.
• W2891917869 creator A5055730299 @default.
• W2891917869 creator A5062220148 @default.
• W2891917869 creator A5064338988 @default.
• W2891917869 creator A5080279805 @default.
• W2891917869 date "2018-11-01" @default.
• W2891917869 modified "2023-10-10" @default.
• W2891917869 title "Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice" @default.
• W2891917869 cites W1946995125 @default.
• W2891917869 cites W1995785495 @default.
• W2891917869 cites W1996308597 @default.
• W2891917869 cites W2017113254 @default.
• W2891917869 cites W2021980805 @default.
• W2891917869 cites W2028202545 @default.
• W2891917869 cites W2043003871 @default.
• W2891917869 cites W2043591841 @default.
• W2891917869 cites W2064775943 @default.
• W2891917869 cites W2073646922 @default.
• W2891917869 cites W2096479500 @default.
• W2891917869 cites W2109752119 @default.
• W2891917869 cites W2112165124 @default.
• W2891917869 cites W2118949910 @default.
• W2891917869 cites W2131078277 @default.
• W2891917869 cites W2133329597 @default.
• W2891917869 cites W2144317224 @default.
• W2891917869 cites W2149435665 @default.
• W2891917869 cites W2168376789 @default.
• W2891917869 cites W2169963977 @default.
• W2891917869 cites W2192794573 @default.
• W2891917869 cites W2195362151 @default.
• W2891917869 cites W2272606123 @default.
• W2891917869 cites W2311072866 @default.
• W2891917869 cites W2344296295 @default.
• W2891917869 cites W2414889538 @default.
• W2891917869 cites W2462321551 @default.
• W2891917869 cites W2726265683 @default.
• W2891917869 cites W2735058696 @default.
• W2891917869 doi "https://doi.org/10.1016/j.msard.2018.09.017" @default.
• W2891917869 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30273841" @default.
• W2891917869 hasPublicationYear "2018" @default.
• W2891917869 type Work @default.
• W2891917869 sameAs 2891917869 @default.
• W2891917869 citedByCount "26" @default.
• W2891917869 countsByYear W28919178692019 @default.
• W2891917869 countsByYear W28919178692020 @default.
• W2891917869 countsByYear W28919178692021 @default.
• W2891917869 countsByYear W28919178692022 @default.
• W2891917869 countsByYear W28919178692023 @default.
• W2891917869 crossrefType "journal-article" @default.
• W2891917869 hasAuthorship W2891917869A5012376027 @default.
• W2891917869 hasAuthorship W2891917869A5017709518 @default.
• W2891917869 hasAuthorship W2891917869A5022338962 @default.
• W2891917869 hasAuthorship W2891917869A5026008723 @default.
• W2891917869 hasAuthorship W2891917869A5026649268 @default.
• W2891917869 hasAuthorship W2891917869A5036189855 @default.
• W2891917869 hasAuthorship W2891917869A5055730299 @default.
• W2891917869 hasAuthorship W2891917869A5062220148 @default.
• W2891917869 hasAuthorship W2891917869A5064338988 @default.
• W2891917869 hasAuthorship W2891917869A5080279805 @default.
• W2891917869 hasBestOaLocation W28919178691 @default.
• W2891917869 hasConcept C118552586 @default.
• W2891917869 hasConcept C126322002 @default.
• W2891917869 hasConcept C141071460 @default.
• W2891917869 hasConcept C159110408 @default.
• W2891917869 hasConcept C1862650 @default.
• W2891917869 hasConcept C187212893 @default.
• W2891917869 hasConcept C197934379 @default.
• W2891917869 hasConcept C2775944032 @default.
• W2891917869 hasConcept C2776036978 @default.
• W2891917869 hasConcept C2777703276 @default.
• W2891917869 hasConcept C2778375690 @default.
• W2891917869 hasConcept C2779134260 @default.
• W2891917869 hasConcept C2779951463 @default.
• W2891917869 hasConcept C2780640218 @default.
• W2891917869 hasConcept C2780892749 @default.
• W2891917869 hasConcept C535046627 @default.
• W2891917869 hasConcept C71924100 @default.
• W2891917869 hasConceptScore W2891917869C118552586 @default.
• W2891917869 hasConceptScore W2891917869C126322002 @default.
• W2891917869 hasConceptScore W2891917869C141071460 @default.
• W2891917869 hasConceptScore W2891917869C159110408 @default.
• W2891917869 hasConceptScore W2891917869C1862650 @default.
• W2891917869 hasConceptScore W2891917869C187212893 @default.
• W2891917869 hasConceptScore W2891917869C197934379 @default.
• W2891917869 hasConceptScore W2891917869C2775944032 @default.
• W2891917869 hasConceptScore W2891917869C2776036978 @default.
• W2891917869 hasConceptScore W2891917869C2777703276 @default.
• W2891917869 hasConceptScore W2891917869C2778375690 @default.
• W2891917869 hasConceptScore W2891917869C2779134260 @default.
• W2891917869 hasConceptScore W2891917869C2779951463 @default.
• W2891917869 hasConceptScore W2891917869C2780640218 @default.

• next